

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM1/21 - Therapeutic Drugs

Deadline: 30.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Set 1																							
(81) Digoxin					16																16	16	100%
Samples and groups		[µg/L]																					
Sample A1			1,39	0,21	15	16															16	16	100%
(4) LIA, ILMA			1,36	0,23	17	10								CRV	1,4	0,014	36%	0,896	1,91		10		
Other					6	0															6		
Sample B1			2,59	0,36	14	16															16	16	100%
(4) LIA, ILMA			2,47	0,41	16	10								CRV	2,57	0,026	36%	1,64	3,5		10		
Other					6	0															6		
														2x 2, 4x 6									
(82) Theophylline					4																4	4	100%
Samples and groups		[mg/L]																					
Sample A1			8,54	1,7	20	4															4	4	100%
Other					4	0															4		
Sample B1			14,6	2,7	19	4															4	4	100%
(4) LIA, ILMA					4	0								CRV	16,51	0,17	24%	12,5	20,5		4		
Other					4	0															4		
														1x 2, 3x 4									
														1x 2, 3x 4									
(84) Phenobarbital					6																6	6	100%
Samples and groups		[mg/L]																					
Sample A1			19,8	0,36	1,8	6	CVP	19,2	0,55	20%	15,3	23,1								6	6	100%	
(4) LIA, ILMA			19,8	0,30	1,5	5	0													5			
Other					1	0														1			
Sample B1			51,1	2,1	4,2	6	CVP	50	1,2	20%	40	60								6	6	100%	
(4) LIA, ILMA			51,5	1,6	3,0	5	0													5			
Other					1	0														1			
							1x 6																
(85) Phenytoin					3																3	2	67%
Samples and groups		[mg/L]																					
Sample A1			12,8	1,8	14	3	CVP	13,3	0,39	20%	10,6	16								3	2	67%	
Other					3	0														3			
Sample B1			19,0	2,9	15	3	CVP	19,7	0,53	20%	15,7	23,7								3	2	67%	
(4) LIA, ILMA					3	0														3			
Other					3	0														3			
							2x 4, 1x 6																
							2x 4, 1x 6																
(86) Carbamazepin					12																12	11	92%
Samples and groups		[mg/L]																					
Sample A1			5,90	0,69	12	12	CVP	5,87	0,16	20%	4,69	7,05								12	11	92%	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM1/21 - Therapeutic Drugs

Deadline: 30.04.2021

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(86) Carbamazepin	[mg/L]				12							12	11	92%									0
Samples and groups																							
Sample A1		5,90	0,69	12	12	CVP	5,87	0,16	20%	4,69	7,05	12	11	92%									0
(4) LIA, ILMA		6,01	0,42	7,0	5	0						5											
Other					7	0						7											
1x 1, 3x 2, 3x 6																							
Sample B1		6,51	0,65	10	12	CVP	6,67	0,15	20%	5,33	8,01	12	11	92%									0
(4) LIA, ILMA		6,50	1,2	19	5	1						5											
Other					7	0						7											
1x 1, 3x 2, 3x 6																							
(88) Valproic acid	[mg/L]				13							13	10	77%									0
Samples and groups																							
Sample A1		78,1	11	14	13	CVP	78,3	1,5	20%	62,6	94	13	10	77%									0
(4) LIA, ILMA		66,1	13	20	5	1						5											
(6) Immunoturbidimetry		81,0	7,4	9,1	5	0						5											
Other					3	0						3											
1x 1, 2x 2																							
Sample B1		96,6	11	11	13	CVP	96,7	1,7	20%	77,3	117	13	11	85%									0
(4) LIA, ILMA		85,1	17	20	5	1						5											
(6) Immunoturbidimetry		100	5,8	5,8	5	0						5											
Other					3	0						3											
1x 1, 2x 2																							
Set 2																							
(89) Amicacin	[mg/L]				4							4	4	100%									0
Samples and groups																							
Sample A2		14,3	1,5	11	4	CVP	14,3	0,31	20%	11,4	17,2	4	4	100%									0
Other					4	0						4											
3x 2, 1x 99																							
Sample B2		6,70	0,74	11	4	CVP	6,38	0,24	20%	5,1	7,66	4	4	100%									0
Other					4	0						4											
3x 2, 1x 99																							
(90) Gentamicin	[mg/L]				11							11	10	91%									0
Samples and groups																							
Sample A2		4,90	0,33	6,8	11	CVP	4,72	0,19	31%	3,25	6,19	11	10	91%									0
(4) LIA, ILMA		4,98	0,11	2,2	5	0						5											
Other					6	0						6											
1x 1, 2x 2, 2x 6, 1x 99																							
Sample B2		11,3	1,3	11	11	CVP	10,6	0,50	31%	7,31	13,9	11	10	91%									0
(4) LIA, ILMA		11,4	0,19	1,6	5	0						5											
Other					6	0						6											
1x 1, 2x 2, 2x 6, 1x 99																							
(92) Vankomycin	[mg/L]				13							13	13	100%									0
Samples and groups																							
Sample A2		17,1	1,5	8,9	13	CVP	17	0,54	28%	12,2	21,8	13	13	100%									0
(4) LIA, ILMA		17,8	0,73	4,1	7	0						7											
Other					6	0						6											
1x 1, 2x 2, 2x 6, 1x 99																							
Sample B2		26,3	2,0	7,7	13	CVP	26,2	0,85	28%	18,8	33,6	13	13	100%									0

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: TDM1/21 - Therapeutic Drugs

Deadline: 30.04.2021

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(92) Vankomycin	[mg/L]				13							13	13	100%									0
Samples and groups																							
Sample B2		26,3	2,0	7,7	13	CVP	26,2	0,85	28%	18,8	33,6	13	13	100%									0
(4) LIA, ILMA		27,4	1,6	5,9	7							7											
Other					6							6											
						1x 1, 2x 2, 2x 6, 1x 99																	
(93) Methotrexate	[µmol/L]				3							3	2	67%									0
Samples and groups																							
Sample A2		2,18	0,65	30	3	CVP	1,67	0,12	30%	1,16	2,18	3	2	67%									0
Other					3							3											
						1x 2, 2x 4																	
Sample B2		5,13	0,47	9,2	3	CVP	4,67	0,25	30%	3,26	6,08	3	3	100%									0
Other					3							3											
						1x 2, 2x 4																	

st_kn_np

End of report

Printed: 05.05.2021